Progyny raises 2026 guidance on strong Q1 performance. The fertility benefits company projects full-year revenue between $1.365 billion and $1.405 billion, while adjusted EBITDA is expected to reach $232 million to $244 million. Management reported record first quarter revenue that exceeded initial expectations, signaling robust demand for its employee fertility and family-building benefits platform. The upward revision reflects confidence in sustained business momentum and operational efficiency gains. This guidance increase demonstrates the company's ability to capitalize on growing employer adoption of comprehensive reproductive health benefits as a competitive advantage in talent retention and acquisition strategies.
Post from MarketNews_en
Log in to interact with content.